Market Overview

Tesaro Volatile After Johnson & Johnson Suspends Enrollment In Prostate Cancer Trial

Related TSRO
Benzinga's Top Upgrades, Downgrades For November 15, 2017
57 Biggest Movers From Yesterday
Your Daily Pharma Scoop: Teva Valuation, DelMar Lead Candidate, Galapagos Commences Trial (Seeking Alpha)

TESARO Inc (NASDAQ: TSRO) shares are trading higher by $0.33 at $140.00 in Friday's session.

The stock fell out of bed around 10:00 a.m. ET, when Johnson & Johnson (NYSE: JNJ) suspended enrollment of Tesaro's Niraparib Phase 2 prostrate cancer trial pending review of data collected.

In a matter of 16 minutes, Tesaro's stock swooned from the $139.00 area all the way to $125.05 before staging a dramatic rebound. The stock was struggling to recover until 11:00 a.m. when Wells Fargo came out and defended the issue.

At this time, the rebound off the low took Tesaro's stock within a few pennies of the session high ($140.74) but retreated to the $140.00 area.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (JNJ + TSRO)

View Comments and Join the Discussion!

Partner Center